Sellas Life Sciences has dosed the first paediatric subject with AML in its Phase II trial of SLS009 (tambiciclib).

According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting ...

Nuance Pharma’s Ohtuvayre has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...